Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 474

1.

Local secretion of IL-12 augments the therapeutic impact of dendritic cell-tumor cell fusion vaccination.

Tan C, Dannull J, Nair SK, Ding E, Tyler DS, Pruitt SK, Lee WT.

J Surg Res. 2013 Dec;185(2):904-11. doi: 10.1016/j.jss.2013.06.045. Epub 2013 Jul 17.

PMID:
23891424
2.

Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model.

Tan C, Reddy V, Dannull J, Ding E, Nair SK, Tyler DS, Pruitt SK, Lee WT.

J Transl Med. 2013 Jun 17;11:148. doi: 10.1186/1479-5876-11-148.

3.

Therapeutic immune response induced by electrofusion of dendritic and tumor cells.

Tanaka H, Shimizu K, Hayashi T, Shu S.

Cell Immunol. 2002 Nov;220(1):1-12.

PMID:
12718934
4.

Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells.

Suzuki T, Fukuhara T, Tanaka M, Nakamura A, Akiyama K, Sakakibara T, Koinuma D, Kikuchi T, Tazawa R, Maemondo M, Hagiwara K, Saijo Y, Nukiwa T.

Clin Cancer Res. 2005 Jan 1;11(1):58-66.

5.
6.

Therapeutic vaccine generated by electrofusion of dendritic cells and tumour cells.

Kuriyama H, Shimizu K, Lee W, Kjaergaard J, Parkhurst MR, Cohen PA, Shu S.

Dev Biol (Basel). 2004;116:169-78; discussion 179-86.

PMID:
15603192
7.
9.

The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.

Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.

Int J Oncol. 2006 Apr;28(4):947-53.

PMID:
16525645
10.

Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines.

Cho EI, Tan C, Koski GK, Cohen PA, Shu S, Lee WT.

Head Neck. 2010 Jun;32(6):700-7. doi: 10.1002/hed.21241.

PMID:
19908319
11.
12.
13.
14.

[Immunotherapeutic reactivity of dendritic cells loaded with a variety of antigen preparations].

Shimizu K, Kuriyama H, Tamai H, Ueda Y, Yamagishi H, Shu S.

Gan To Kagaku Ryoho. 2004 Oct;31(11):1637-9. Japanese.

PMID:
15553668
15.

Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.

Tüting T, Steitz J, Brück J, Gambotto A, Steinbrink K, DeLeo AB, Robbins P, Knop J, Enk AH.

J Gene Med. 1999 Nov-Dec;1(6):400-6.

PMID:
10753065
16.

Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon.

Abdel-Wahab Z, Dar M, Osanto S, Fong T, Vervaert CE, Hester D, Jolly D, Seigler HF.

Cancer Gene Ther. 1997 Jan-Feb;4(1):33-41.

PMID:
9012449
17.

Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.

Galea-Lauri J, Wells JW, Darling D, Harrison P, Farzaneh F.

Cancer Immunol Immunother. 2004 Nov;53(11):963-77. Epub 2004 May 14.

PMID:
15146294
18.

Induction of anti-tumor immunity by vaccination with dendritic cells pulsed with anti-CD44 IgG opsonized tumor cells.

Pilon-Thomas S, Verhaegen M, Kuhn L, Riker A, Mulé JJ.

Cancer Immunol Immunother. 2006 Oct;55(10):1238-46. Epub 2005 Nov 29.

PMID:
16315029
19.

Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.

Tanaka Y, Koido S, Ohana M, Liu C, Gong J.

J Immunol. 2005 Feb 1;174(3):1274-80.

20.

Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2.

Shimizu K, Fields RC, Redman BG, Giedlin M, Mulé JJ.

Cancer J Sci Am. 2000 Feb;6 Suppl 1:S67-75.

PMID:
10685663

Supplemental Content

Support Center